Polio vaccine provides 3-week immunity

Dr. Mikhail Chumakov, while doing polio research in 1956 with Dr. Sabin noted that live polio vaccine appeared to provide temporary (3-week) immunity against the influenza virus.  Mikhail's son, Konstatin Chumakov became an eminent virologist in his own right, and emigrated to the U.S., where he now works for the FDA  on creation of new methods for development and evaluation of vaccines against viral diseases.  His main focus is still on studying poliovirus and poliovirus vaccines.  He mentioned the temporary immunity effect of OPV against coronaviruses while speaking about his parents' contribution to virology (see minute 28:00 in his interview  https://www.globalhealthchronicles.org/items/show/8089  ).   Dr. Bob Gallo found this observation very pertinent to today's need for covid-19 immunitiy and brought this early work back under the spotlight with an article in USA Today, co-authored by Konstantin Chumakov - see  https://amp.usatoday.com/amp/5162859002 .  Oral polo vaccine (OPV) has been extensively studied, and seems to be worthly of evaluation as a short-term immunizer against covid-19. The downside is that the classic Sabin OPV is gentically unstable (it can mutate).  Dr. Chumakov is currently researching new, more stable versions of the vaccine.  His latest paper is "Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization" (see Nature https://www.nature.com/articles/s41541-020-0176-7 ).   Len it would be great to hear your take on this approach.

Regards, Mort Hjortsvang